"Black Box" Will Not Deter Off-Label Zyprexa Use In Dementia Patients, Lilly Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company points to the lack of indicated alternatives for treating dementia-related psychosis as one reason why psychiatrists will continue to prescribe atypical antipsychotics despite a new "black box" warning on mortality in that patient population. First quarter U.S. Zyprexa sales fell 17% compared to the same period in 2004.
You may also be interested in...
Lilly To Pay Up To $690 Mil. To Settle Majority Of Zyprexa Injury Claims
Settlement will cover approximately 8,000 personal injury claims regarding diabetes and hyperglycemia, or about 75% of the total number of cases, Lilly says. “Lilly is prepared to continue its vigorous defense of Zyprexa in the remaining cases,” the company said.
Lilly To Pay Up To $690 Mil. To Settle Majority Of Zyprexa Injury Claims
Settlement will cover approximately 8,000 personal injury claims regarding diabetes and hyperglycemia, or about 75% of the total number of cases, Lilly says. “Lilly is prepared to continue its vigorous defense of Zyprexa in the remaining cases,” the company said.
Lilly Zyprexa Patent Upheld On All Counts
The district court ruling means that generic versions of olanzapine are unlikely to enter the market before 2011, when the only "Orange Book" listed patent for Zyprexa is set to expire.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: